Masters Programme Endorsed by Leading Multinational Top 20 Pharmaceutical Companies Through the Asia Training Consortium
ClinTec International and Edinburgh Napier University are delighted to announce that the Asia Training Consortium has endorsed the Masters in International Clinical Research and Technology for clinical research professionals.
The Asia Training Consortium (ATC) was founded in 2012 as a unified platform for pharmaceutical companies to establish common goals and share resources to provide world-class training and development in clinical research in Asia. It is currently a consortium of 17 companies, including large top 20 pharmaceutical companies such as Merck, Novartis, Pfizer, Astellas and AstraZeneca, global CROs and training institutions including Edinburgh Napier University. This is the first endorsement from ATC of an academic qualification to meet the needs for further qualifications for research professionals.
The Masters in International Clinical Research and Technology was launched last year between Edinburgh Napier University and ClinTec International to support the development of clinical research staff throughout the world and has now been endorsed by the ATC. This innovative Masters programme is an exciting collaboration, which builds upon the clinical research and educational expertise that exists within these two organisations. The Masters programme is accessible globally and has enrolled students from 14 countries, including students based in UAE, Lebanon, South Africa, India and the Philippines, as well as from France, Austria, Sweden, UK, Czech Republic, Slovenia, Lithuania, Croatia and Romania. This successful innovative industry/academic collaboration leading to a Masters Degree led to ClinTec being awarded the Microsoft Innovation of the Year Award 2014 at the UK’s largest Business Award Ceremony, with guest speaker global entrepreneur, Sir Richard Branson. Over the last 5 years, ClinTec and Edinburgh Napier University have delivered clinical research courses to over 1000 clinical professionals globally, with over 200 based in Asia.
ClinTec International is a global CRO, with a presence in over 50 countries across 5 continents. On the occasion of the endorsement of the Masters programme by ATC, Dr Rabinder Buttar, Founder, Chairman and CEO of ClinTec International, commented: “ClinTec International is delighted to receive this endorsement from the Asia Training Consortium. As ClinTec has a global presence in over 50 countries, we are very pleased to be associated with a platform that provides world-class training and development in Asia”.
Professor Andrea Nolan, Principal and Vice-Chancellor of Edinburgh Napier University stated: “At Edinburgh Napier University we have a history of collaborating with industry to give students the best possible education to equip them to become leaders in their field. We are delighted to have the endorsement from the Asia Training Consortium who share the joint aspirations of providing world class training for clinical research professionals”.
John Constantine, Chair, Asia Training Consortium, said: “This is yet another example of collaboration within and across industries to further quality and excellence in clinical research. ATC membership is excited to have this endorsement between a respected University, Edinburgh Napier University, and ClinTec, one of the premier contract research organizations. I look forward to further collaborations like this between ATC members in the future.”
Related News
-
News Federal judge blocks Colorado's unprecedented price cap on Amgen's Enbrel
A US federal court has halted Colorado's attempt to impose a US$31,200 annual price cap on Amgen's arthritis drug Enbrel, ruling that the pharmaceutical company would likely suffer irreparable harm. The decision represents a significant blow to... -
News Protecting life-saving therapies: CPHI Online Podcast Series
The latest episode of the CPHI Podcast Series dives into a critical challenge facing the pharmaceutical industry: ensuring the integrity of temperature-sensitive medications and biologics through advanced predictive technology.
-
News 2026 Outsourcing Outlook Update - pharma at a crossroads
The pharmaceutical contract development and manufacturing organisation (CDMO) sector is experiencing unprecedented transformation, driven by evolving therapeutic complexities, geopolitical tensions, and the growing demand for specialised manufacturing ... -
News Roche maintains German investment commitment whilst rivals scale back
Pharmaceutical giant Roche has reaffirmed its commitment to investing in Germany, standing firm even as competitors Eli Lilly and Boehringer Ingelheim dramatically reduce their planned investments in response to controversial healthcare reforms.
-
News Women in Pharma: The History of CPHI Women in Japan
Our monthly Women in Pharma series highlights the influential lives and work of impactful women working across the pharmaceutical industry, and how the industry can work towards making the healthcare industry and workplace more equitable and inclusive. -
News EU drafts deal to end essential medicines shortage
European negotiators have agreed new legislation to tackle persistent shortages of essential medicines by prioritising supply security over price in public procurement and supporting domestic pharmaceutical manufacturing with strategic funding.
-
News Thermo Fisher Scientific offloads microbiology business to PE firm Astorg
The life sciences giant is divesting its global microbiology unit, which generated $645 million in revenue last year, to the pan-European private equity firm as part of an active portfolio management strategy. The transaction is expected to close in th... -
News The Shift: Why Sustainability is Moving to the Centre of CPHI Milan 2026
CPHI Online contributor David Roach takes a look at how conversations around sustainability in the pharmaceutical industry can and must be transformed into actionable deliveries, and what the inaugural CPHI Sustainability Summit means for the industry.